Daito Pharmaceutical Co Ltd
TSE:4577
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 807
2 542
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Daito Pharmaceutical Co Ltd
Cost of Revenue
Daito Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Daito Pharmaceutical Co Ltd
TSE:4577
|
Cost of Revenue
-ÂĄ37.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
||
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cost of Revenue
-ÂĄ1.5T
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
||
Daiichi Sankyo Co Ltd
TSE:4568
|
Cost of Revenue
-ÂĄ420B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
||
Otsuka Holdings Co Ltd
TSE:4578
|
Cost of Revenue
-ÂĄ648.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
||
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cost of Revenue
-ÂĄ337.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
||
Astellas Pharma Inc
TSE:4503
|
Cost of Revenue
-ÂĄ383.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
Daito Pharmaceutical Co Ltd
Glance View
Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.
See Also
What is Daito Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-37.8B
JPY
Based on the financial report for Aug 31, 2024, Daito Pharmaceutical Co Ltd's Cost of Revenue amounts to -37.8B JPY.
What is Daito Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-4%
Over the last year, the Cost of Revenue growth was -7%. The average annual Cost of Revenue growth rates for Daito Pharmaceutical Co Ltd have been -2% over the past three years , -2% over the past five years , and -4% over the past ten years .